Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Skin Laboratory PCL's long-term debt to total assests ratio for the quarter that ended in Mar. 2026 was 0.00.
Skin Laboratory PCL's long-term debt to total assets ratio
declined
from Dec. 2024 (0.02) to Mar. 2026 (0.00).
It may suggest that Skin Laboratory PCL is progressively becoming less dependent on debt to grow their business.
LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.
Skin Laboratory PCL LT-Debt-to-Total-Asset Related Terms
Skin Laboratory PCL LT-Debt-to-Total-Asset Historical Data
* Premium members only.
The historical data trend for Skin Laboratory PCL's LT-Debt-to-Total-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Skin Laboratory PCL (BKK:SKIN) has a LT-Debt-to-Total-Asset of 0.00 as of Mar. 2026. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Skin Laboratory PCL and its competitors.
Is Skin Laboratory PCL's LT-Debt-to-Total-Asset too high?
Skin Laboratory PCL's current LT-Debt-to-Total-Asset is 0.00. Overall, Skin Laboratory PCL has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Skin Laboratory PCL's LT-Debt-to-Total-Asset compare to PG and CL?
Skin Laboratory PCL's LT-Debt-to-Total-Asset of 0.00 can be compared against companies in the Consumer Packaged Goods industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good LT-Debt-to-Total-Asset for a Consumer Packaged Goods company?
A good LT-Debt-to-Total-Asset depends on the Consumer Packaged Goods industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high LT-Debt-to-Total-Asset mean?
A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Skin Laboratory PCL and its competitors. Skin Laboratory PCL's current LT-Debt-to-Total-Asset is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Skin Laboratory PCL stock overvalued right now?
Skin Laboratory PCL (BKK:SKIN) has a current LT-Debt-to-Total-Asset of 0.00. The current LT-Debt-to-Total-Asset is 0.00. Skin Laboratory PCL's overall GF Score™ is 20/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is LT-Debt-to-Total-Asset calculated?
LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Skin Laboratory PCL (BKK:SKIN), the current LT-Debt-to-Total-Asset is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Skin Laboratory PCL is engaged in the business of inventing, developing, contracting production, and distributing beauty products under the Company's various brands, including facial serum products, sunscreen products, facial cleansers, facial care products, and other products. The Company's core business is only one operating segment, which is manufacturing and distributing skin creams, beauty creams, cosmetics, and operates virtually its business in one geographical location in Thailand.
20GF Score
Get the complete analysis for BKK:SKIN
LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BKK:SKIN has been successfully added to your 
